ClinicalTrials.gov
ClinicalTrials.gov Menu

Cell-Wave Study: Combined Extracorporal Shock Wave Therapy and Intracoronary Cell Therapy in Chronic Ischemic Myocardium

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00326989
Recruitment Status : Completed
First Posted : May 17, 2006
Last Update Posted : March 21, 2017
Sponsor:
Information provided by (Responsible Party):
A. M. Zeiher, Johann Wolfgang Goethe University Hospital

Brief Summary:

Extracorporal shock wave therapy is performed prior to cell therapy for induction of therapeutic neovascularization and improvement of homing of bone marrow progenitor cells in patients with chronic ischemic heart disease following anterior myocardial infarction.

Shock waves can induce growth factor expression in the ischemic myocardium and might augment homing of autologous bone marrow mononuclear cells which are injected intracoronary 24 h following shock wave therapy


Condition or disease Intervention/treatment Phase
Congestive Heart Failure Procedure: intracoronary stem cell therapy Phase 1 Phase 2

Detailed Description:
Single center, Phase I-II Study (Safety, Feasibility and Efficacy) Double-blind, randomised trial (Cell therapy), single blind (Shockwave)

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 103 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: Extracorporal Shock Wave Therapy for Induction of Therapeutic Neovascularization and Homing of Bone Marrow Progenitor Cells in Patients With Chronic Ischemic Heart Disease
Study Start Date : May 2006
Actual Primary Completion Date : September 2011
Actual Study Completion Date : December 2011

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Shock
U.S. FDA Resources

Arm Intervention/treatment
Active Comparator: Low-dose shock wave treatment & Placebo Procedure: intracoronary stem cell therapy
extracorporal shock waves prior to intracoronary cell therapy
Active Comparator: low-dose shock-wave treatment & Cell therapy Procedure: intracoronary stem cell therapy
extracorporal shock waves prior to intracoronary cell therapy
Active Comparator: High-dose shock-wave treatment & Placebo Procedure: intracoronary stem cell therapy
extracorporal shock waves prior to intracoronary cell therapy
Active Comparator: High-dose shock-wave treatment & cell therapy Procedure: intracoronary stem cell therapy
extracorporal shock waves prior to intracoronary cell therapy
Active Comparator: Placebo shock-wave treatment & cell therapy Procedure: intracoronary stem cell therapy
extracorporal shock waves prior to intracoronary cell therapy



Primary Outcome Measures :
  1. Improvement in global ejection fraction on LV angiography [ Time Frame: 4 months ]

Secondary Outcome Measures :
  1. Global or regional wall motion at 4 months and 1 year [ Time Frame: 4 months ]
  2. NYHA Class [ Time Frame: 4 months ]
  3. NT BNP levels [ Time Frame: 4 months ]
  4. MACE [ Time Frame: 4 months ]
  5. Life quality [ Time Frame: 4 months ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients with chronic ischemic heart disease
  • Patients with anterior myocardial infarction > 3months
  • EF < 50% or NYHA II-IV
  • Age 18-80
  • Informed consent

Exclusion Criteria:

  • Ventricular thrombus
  • Infarct < 3 months.
  • Active infection or fever
  • Chronic inflammatory disease (e.g M. Crohn, Rheumatoid Arthritis)
  • HIV Infection oder active Hepatitis
  • Neoplastic disease w/o complete remission within 5 years
  • Stroke < 3months
  • Creatinine > 2 mg/dl
  • Relevant Liver disease (GOT > twice the upper limit).
  • Anemia (Hemoglobin <10 mg/dl)
  • Thrombocytopenia < 100.000/µl
  • Allergies to Aspirin, Clopidogrel, Heparin
  • History of bleeding disorder
  • History of coagulopathy
  • Gastrointestinal Bleeding < 3 months
  • Surgery or Trauma < 2 months
  • Pregnancy
  • Mental Retardation
  • Participation in other clinical study < 1 month

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00326989


Locations
Germany
Div. of Cardiology , University of Frankfurt
Frankfurt, Germany, 60590
Sponsors and Collaborators
Johann Wolfgang Goethe University Hospital
Investigators
Principal Investigator: Andreas M Zeiher, MD Div. of Cardiology, University of Frankfurt, Germany
Study Director: Dirk H Walter, MD Div. of Cardiology, University of Frankfurt

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: A. M. Zeiher, Prof. Dr. Andreas M. Zeiher, Johann Wolfgang Goethe University Hospital
ClinicalTrials.gov Identifier: NCT00326989     History of Changes
Other Study ID Numbers: 2005-005709-50
Cellwave CHF
First Posted: May 17, 2006    Key Record Dates
Last Update Posted: March 21, 2017
Last Verified: March 2017

Keywords provided by A. M. Zeiher, Johann Wolfgang Goethe University Hospital:
Extracorporal shock wave therapy
Cell therapy

Additional relevant MeSH terms:
Heart Failure
Heart Diseases
Cardiovascular Diseases